Trovagene Inc (NASDAQ:TROV)’s Trend Unknown, Especially After Increased Shorts

October 13, 2018 - By Michael Collier

TrovaGene, Inc. (NASDAQ:TROV) Logo

The stock of Trovagene Inc (NASDAQ:TROV) registered an increase of 149.38% in short interest. TROV’s total short interest was 599,000 shares in October as published by FINRA. Its up 149.38% from 240,200 shares, reported previously. With 917,000 shares average volume, it will take short sellers 1 days to cover their TROV’s short positions. The short interest to Trovagene Inc’s float is 3.73%.

The stock increased 7.39% or $0.0596 during the last trading session, reaching $0.8656. About 1.28M shares traded or 8.56% up from the average. TrovaGene, Inc. (NASDAQ:TROV) has declined 91.22% since October 13, 2017 and is downtrending. It has underperformed by 106.84% the S&P500.

Trovagene, Inc., a molecular diagnostic company, focuses on the development and commercialization of proprietary molecular genetic detection technology for use in pharmaceutical development, clinical research, and medical testing in various clinical disciplines in the United States. The company has market cap of $15.31 million. The firm intends to enhance the treatment outcomes for cancer patients through its proprietary technology to detect and quantitatively monitor circulating tumor DNA using urine or blood samples. It currently has negative earnings. It offers Precision Cancer Monitoring (PCM) platform, which provides cancer monitoring by tracking and quantifying levels of ctDNA from either urine or blood samples, as well as intends to offer clinical information beyond the current standard of care.

TrovaGene, Inc. (NASDAQ:TROV) Ratings Coverage

Among 2 analysts covering TrovaGene (NASDAQ:TROV), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. TrovaGene had 4 analyst reports since June 4, 2018 according to SRatingsIntel. The stock has “Buy” rating by Maxim Group on Friday, June 15. The firm has “Buy” rating by H.C. Wainwright given on Tuesday, June 19. The firm has “Buy” rating given on Monday, June 11 by H.C. Wainwright. H.C. Wainwright maintained the shares of TROV in report on Monday, June 4 with “Buy” rating.

Another recent and important TrovaGene, Inc. (NASDAQ:TROV) news was published by which published an article titled: “Trovagene inks deal with MIT for combination therapy of anti-androgens and PLK inhibitors in prostate cancer; shares …” on October 03, 2018.

TrovaGene, Inc. (NASDAQ:TROV) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News